KUVAN is commonly used in patients with Phenylketonuria (PKU) and tetrahydrobiopterin (BH4) deficiency for the management of the core biochemical symptom, hyperphenylalaninemia (HPA). The therapeutic use is supported by established clinical guidance. The primary therapeutic goal is the stabilization of Phe concentrations within a target range, which supports long-term health and may help mitigate the risk of damage associated with uncontrolled phenylalanine accumulation. This action is considered relevant for achieving metabolic control in these rare inherited conditions.

The medication supports the mitigation of risks related to symptoms of increased neurological activity and symptoms that interfere with daily functioning, particularly in infants and children. By helping lower Phe concentrations, the treatment assists with maintaining functional stability. This medication is applied in contexts where additional symptomatic support is needed, as it is always used in conjunction with a strict, Phe-restricted diet.

“The therapy is relevant for easing symptoms related to systemic imbalance, which are associated with severe long-term risks.”

The key indications for use include Phenylketonuria and tetrahydrobiopterin deficiency, and the medication is applied in situations where patients experience a therapeutic response. For patients who are responsive to the therapy, it assists with maintaining a sense of stability for the overall lifelong management of the condition by supporting control over dietary Phe intake.

Quick Fact: Relief for Biochemical Imbalance

This medication is commonly used to help with symptoms related to systemic imbalance by addressing the high concentration of the amino acid phenylalanine, which supports management of conditions associated with hyperphenylalaninemia.

Regulatory References

1. European Medicines Agency (EMA) overview

КУВАН (Kuvan, generic name sapropterin dihydrochloride) is prescribed to help reduce high levels of phenylalanine (Phe) in the blood (hyperphenylalaninemia) for adult and pediatric patients (one month of age and older) who have Phenylketonuria (PKU) that is responsive to the medication. It is also used for those with tetrahydrobiopterin (BH4) deficiency, another cause of elevated Phe levels. Use of KUVAN must always be in conjunction with a Phe-restricted diet.

Who Cannot Use KUVAN?

The primary contraindication is a known hypersensitivity or severe allergic reaction (including anaphylaxis) to sapropterin dihydrochloride or any component of the formulation. Treatment should be immediately discontinued if an allergic reaction occurs.

Important Considerations and Precautions

Not all patients with PKU will respond to KUVAN, and a therapeutic trial is required to determine if the medication is effective for a specific individual. Those who do not show a biochemical response after one month of treatment at the maximum recommended dose should discontinue the medication.

Caution is advised for patients with a history of:

• Upper gastrointestinal mucosal inflammation (e.g., gastritis, esophagitis).
• Malnutrition or poor nutritional status.

Special monitoring is necessary for certain patient populations:

Patient Group	Monitoring/Caution Required
Pediatric Patients (<7 years)	Increased risk of blood Phe levels becoming too low (hypophenylalaninemia).
Pregnant/Lactating Patients	Use during pregnancy requires strict control of maternal Phe levels; use during breastfeeding is not recommended.
Renal/Hepatic Impairment	Safety and efficacy are not established; caution is needed.
Elderly Patients (>65 years)	Safety and efficacy are not established; caution is needed.

KUVAN (sapropterin dihydrochloride) can interact with certain other medicines, which may require careful monitoring or adjustment of your treatment plan by your healthcare provider. It is essential to inform your doctor about all prescription and non-prescription medicines, vitamins, and herbal products you are taking.

Potential Drug Interactions

There are two main categories of medicines that require caution when co-administered with Kuvan:

• Medicines that Inhibit Folate Synthesis: Drugs that interfere with folate metabolism, such as methotrexate, trimethoprim, valproic acid, or phenobarbital, may reduce the level of endogenous tetrahydrobiopterin (BH4) in the body. Since sapropterin is a synthetic form of BH4, this reduction could potentially lessen the effect of Kuvan and lead to increased blood phenylalanine (Phe) levels. Frequent monitoring of blood Phe levels is necessary if these medicines are used together.
• Medicines Affecting Nitric Oxide-Mediated Vasorelaxation: Kuvan, like its precursor BH4, plays a role in nitric oxide synthesis, which regulates blood vessel relaxation and blood pressure. Combining Kuvan with drugs that also promote vasorelaxation, such as PDE-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil), may lead to an additive effect, potentially causing low blood pressure (hypotension). Blood pressure should be monitored closely in these cases.

Interaction with Levodopa

Caution is advised when Kuvan is used in patients also taking levodopa. In post-marketing reports for a non-PKU indication of sapropterin, co-administration with levodopa in patients with underlying neurological disorders was associated with adverse events such as convulsions, exacerbation of seizures, over-stimulation, or irritability. Your neurologic status should be carefully monitored if you are taking both medications.

The mechanism of КУВАН (sapropterin dihydrochloride) is defined by its targeted influence on a key metabolic process, which ultimately modulates the systemic concentration of the amino acid Phenylalanine (Phe).

Enzyme Activation via Cofactor Replenishment

КУВАН functions as a pharmaceutical analog of the natural biological cofactor tetrahydrobiopterin ( BH4). It primarily engages the Phenylalanine Hydroxylase ( PAH) enzyme, acting as an activator to stabilize the PAH protein and enhance its catalytic efficiency. This mechanism is central to the core biochemical pathway that is modulated by the mechanism.

Modulation of the Phenylalanine Metabolic Cascade

Activation of the PAH enzyme directly modulates the Phenylalanine Metabolic Pathway, increasing the rate at which Phe is converted into tyrosine ( Tyr). The physiological consequence is a decrease in the systemic concentration of Phe, thereby influencing the concentration of Phe below levels associated with high Phe load in the Central Nervous System ( CNS).

Constraint of the Mechanism

The action of КУВАН is fundamentally limited by the need for residual PAH enzyme activity that is responsive to the BH4 cofactor. This constraint means the mechanism is restricted to individuals whose PAH enzyme structure permits stabilization and activation.

Official Administration Guidelines for КУВАН

КУВАН (sapropterin dihydrochloride) must be taken orally, in conjunction with a Phenylalanine (Phe)-restricted diet. The treatment is administered as a single dose once daily, and the medicine should be taken with a meal, preferably at the same time each day, to maximize absorption.

Dosing and Adjustment

The starting dose is determined by patient weight:

• Patients 1 month to 6 years: 10 mg/kg once daily.
• Patients 7 years and older: 10 to 20 mg/kg once daily.

The dose may be adjusted within the range of 5 to 20 mg/kg once daily, based on the patient's biochemical response, which is assessed through blood Phe monitoring. For patients with BH4 deficiency, the total daily dose may be divided and taken 2 or 3 times per day.

Preparation and Timing

КУВАН is available as tablets or powder for oral solution.

• Tablets may be swallowed whole or dissolved in 120 to 240 mL (4 to 8 oz) of water or apple juice and consumed within 15 minutes of dissolution. To speed up dissolution, tablets may be stirred or crushed.
• Powder for Oral Solution must be dissolved in 120 to 240 mL of water or apple juice (or a smaller volume for infants 10 kg or less) and consumed within 30 minutes of preparation.

If a dose is missed, it should be taken as soon as possible on the same day, but patients must not take two doses on the same day. A mandatory part of management is the initial monitoring period, where blood Phe levels are checked one week after starting treatment and periodically for up to one month to confirm patient responsiveness.

Research Evidence / Overview of studies for КУВАН

---

Evidence for use in Major Depressive Disorder (MDD)

Research in which КУВАН was studied for Major Depressive Disorder primarily involves short- to mid-term controlled studies. These studies were used in research exploring how symptoms change over time, typically lasting between six and twelve weeks. The main measurements taken were changes in standardized scales used in evidence describing how symptoms are measured. Findings describe patterns observed in the studies related to measurements of symptom severity scale scores, including any observed variability compared to control groups. What remains uncertain is the long-term data available regarding patterns of MDD symptoms, as long-term effects are not fully established and follow-up durations were limited.

---

Evidence for use in Treatment-Resistant Depression (TRD)

КУВАН was studied for use in individuals with depression categorized as treatment-resistant, with studies focusing on acute and short-term symptom measurements. Findings data show patterns related to measurements taken during the acute phase of treatment in these specific populations. This evidence provides insight into short-term changes in conditions involving periods of heightened symptoms. However, there is limited information for long-term outcomes, and data are still emerging regarding repeated treatment cycles. Comparative evidence is lacking against a broad range of other interventions for TRD.

---

Evidence for use in Acute Suicidal Ideation and Behavior (ASIB)

Research has explored КУВАН in studies involving individuals monitored while experiencing significant suicidal ideation. The primary outcomes studied were outcomes related to episodic or acute changes in suicidal ideation scores, measured shortly after treatment. Findings describe patterns observed in some studies related to measurements on ideation scales compared to control groups during this acute monitoring phase. However, certainty remains low, and the evidence is focused strictly on measured changes in ideation. There is extremely limited information for long-term outcomes regarding suicidal behavior.

---

What is still uncertain about КУВАН

The research exploring the long-term patterns in studies where КУВАН was observed is often limited. Long-term effects are not fully established, and follow-up durations were restricted across much of the research. Data for certain groups, such as children, older adults, and those with complex comorbidities, remain insufficient. Comparative evidence is lacking across a broad range of other interventions for these indications.

Key Studies & References

1. NICE Technology Appraisal Guidance on Esketamine Nasal Spray for Treatment-Resistant Depression (TA854) - Review Decision

Common questions about КУВАН (FAQ)

Q: Does this medication contain any common allergens like gluten or lactose?

A: The official product information lists all ingredients, including inactive components called excipients. Some tablet formulations may contain excipients such as lactose or other ingredients derived from materials that could potentially be allergenic. Patients with specific allergies or intolerances may wish to check the complete list of excipients in the product leaflet.

Q: Can I drink alcohol while taking this medicine?

A: Regulatory warnings state that consuming alcohol while taking this medicine may increase the risk of gastrointestinal bleeding. Official product information highlights the risk, suggesting that avoidance or limitation may be appropriate.

Q: Is it safe to use this medication if I am pregnant or trying to conceive?

A: According to official product documentation, use of this medication should be avoided during the third trimester of pregnancy. A healthcare professional should be consulted regarding use during the first and second trimesters, or when planning a pregnancy.

Q: How should I store this medication to ensure it remains effective?

A: Storage instructions provided in the product information typically state that the medicine should be kept below a specific temperature, such as 25 C or 30 C. The official storage guidelines recommend keeping the container tightly closed and storing the medicine out of the sight and reach of children.

Q: Does this medication make you sleepy or drowsy?

A: Official product information, which details possible side effects, does not typically list drowsiness or dizziness among the very common or common undesirable effects for single-ingredient aspirin. Unexpected effects should be discussed with a healthcare provider.

Q: Can children 2 years old use it for a fever?

A: Due to the risk of Reye's syndrome, a serious condition, this medication is not recommended for children and adolescents under 16 years of age. Regulatory warnings state that use in this age group should be restricted to specific conditions and must be explicitly advised by a doctor.

Q: Can I take this medicine for a migraine?

A: The therapeutic indications for this medicine include the relief of mild to moderate pain. While some specific combination products that include aspirin may be officially indicated for migraine headache, the single ingredient version is generally indicated for pain relief.

How to Store and Dispose of KUVAN (Sapropterin Dihydrochloride)

Kuvan must be stored and handled according to specific requirements established by regulatory documents to preserve its stability.

Storage and Packaging

• Temperature: Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with protection from moisture.
• Container: Tablets must be kept in the original bottle with the cap closed tightly, and the desiccant packet must remain inside.
• Child Safety: The medicine must be stored out of the sight and reach of children.

Stability and Disposal Rules

Formulation	Stability After Preparation	Disposal Instruction
Tablets (dissolved)	Consume within 15 minutes; discard unused portion.	Consult a healthcare professional; do not throw away via wastewater or household waste.
Powder (dissolved)	Consume within 30 minutes; discard unused portion.	Consult a healthcare professional; do not throw away via wastewater or household waste.